Prescription of potentially addictive medications after a multilevel community intervention in general practice

Abstract Objective To evaluate the long-term effects of a multilevel community intervention to improve the quality of prescription practice of potentially addictive medications (PAMs). Design We conducted a retrospective study, using anonymized data from the Norwegian prescription registry. Setting Based on an initiative from the GPs in Molde Municipality in Norway, a multilevel community intervention was initiated by the municipal chief physician in 2018. The intervention targeted GPs, patients, and the public. Subjects We retrieved prescription data from 26 of 36 GPs. Main outcome measures By using the standardized defined daily dose (DDD), we compared prescription of three groups of PAMs from before the intervention (2017) throughout the intervention in 2018, and through 2020 to determine long-term effects. Results Three years after the intervention, the GPs in our study sample prescribed 26% less opioids, 38% less benzodiazepines, and 16% less z-hypnotics. Overall prescription of PAMs decreased by 27%. The number of individuals receiving at least 90 DDD of benzodiazepines and z-hypnotics were reduced from 9 to 7 and 34 to 24 per 1000, respectively. Also, the number of individuals receiving two and three PAMs concomitantly were reduced. Conclusion Addressing prescription practice among GPs in a community as a joint intervention, combined with addressing patients and the public may be a feasible method to obtain long-term reduction of PAM prescriptions. Key points Non-therapeutic prescriptions of potentially addictive medications (PAMs) are both a public health concern and a frequent challenge in general practice. A multilevel community intervention, targeting general practitioners, patients, and the public, led to 27% reduction in prescription of PAMs. Both the number of daily users and concomitant use of several PAMs were reduced. The reduction in prescription persisted for three years.

[1]  B. Koes,et al.  Opioid reduction for patients with chronic pain in primary care: systematic review , 2022, The British journal of general practice : the journal of the Royal College of General Practitioners.

[2]  S. Leblanc,et al.  The CFIR Card Game: a new approach for working with implementation teams to identify challenges and strategies , 2021, Implementation Science Communications.

[3]  A. Mygind,et al.  Exploring implementation processes in general practice in a feedback intervention aiming to reduce potentially inappropriate prescribing: a qualitative study among general practitioners , 2021, Implementation Science Communications.

[4]  C. Ashton-James,et al.  Deprescribing long‐term opioid therapy in patients with chronic pain , 2020, Internal medicine journal.

[5]  C. Maher,et al.  Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials , 2020, Drugs.

[6]  Keith Wong,et al.  Benzodiazepine use risk: Understanding patient specific risk perceptions and medication beliefs. , 2019, Research in social & administrative pharmacy : RSAP.

[7]  A. Bérard,et al.  Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion. , 2019, JAMA psychiatry.

[8]  William J. Parish,et al.  Opioid medication discontinuation and risk of adverse opioid-related health care events. , 2019, Journal of substance abuse treatment.

[9]  D. Juurlink,et al.  Prevention of Opioid Overdose. , 2019, The New England journal of medicine.

[10]  T. Clausen,et al.  Prescribed opioid analgesic use developments in three Nordic countries, 2006–2017 , 2019, Scandinavian journal of pain.

[11]  R. McHugh,et al.  Review: Adjunctive pharmacologic approaches for benzodiazepine tapers. , 2018, Drug and alcohol dependence.

[12]  N. van der Velde,et al.  Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. , 2018, Journal of the American Medical Directors Association.

[13]  M. Petrovic,et al.  A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people , 2017, European Journal of Clinical Pharmacology.

[14]  J. Hewitt,et al.  Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis , 2017, PloS one.

[15]  Folkehelseinstituttet Bruk av vanedannende legemidler i Norge 2005-2013 , 2015 .

[16]  J. Wyatt,et al.  Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide , 2014, BMJ : British Medical Journal.

[17]  A. Siriwardena,et al.  General practitioners’ experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesis , 2013, BMC Family Practice.

[18]  M. Petrovic,et al.  The lesser evil? Initiating a benzodiazepine prescription in general practice , 2007, Scandinavian journal of primary health care.

[19]  Trine Bjørner,et al.  Factors associated with high prescribing of benzodiazepines and minor opiates , 2003, Scandinavian journal of primary health care.

[20]  Karin Drivenes,et al.  Reduksjon i forbruket av vanedannende legemidler i Vest-Agder , 2001 .

[21]  G. Mouland Brev til brukere av benzodiazepiner - en effektiv måte å få ned forskrivningen på , 1997 .

[22]  J. Straand,et al.  Can drug treatment be improved by feedback on prescribing profiles combined with therapeutic recommendations? A prospective, controlled trial in general practice. , 1995, Journal of clinical epidemiology.

[23]  C. I. Neutel,et al.  Multiple prescribers in older frequent opioid users--does it mean abuse? , 2013, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.